GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (FRA:2F5) » Definitions » Altman Z-Score

Scinai Immunotherapeutics (FRA:2F5) Altman Z-Score : -10.73 (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scinai Immunotherapeutics Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -10.71 is in distress zone. This implies bankruptcy possibility in the next two years.

Scinai Immunotherapeutics has a Altman Z-Score of -10.73, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Scinai Immunotherapeutics's Altman Z-Score or its related term are showing as below:

FRA:2F5' s Altman Z-Score Range Over the Past 10 Years
Min: -12.42   Med: 0.67   Max: 24.18
Current: -10.71

During the past 13 years, Scinai Immunotherapeutics's highest Altman Z-Score was 24.18. The lowest was -12.42. And the median was 0.67.


Scinai Immunotherapeutics Altman Z-Score Historical Data

The historical data trend for Scinai Immunotherapeutics's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Altman Z-Score Chart

Scinai Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scinai Immunotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -12.42 -10.69

Competitive Comparison of Scinai Immunotherapeutics's Altman Z-Score

For the Biotechnology subindustry, Scinai Immunotherapeutics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Altman Z-Score falls into.



Scinai Immunotherapeutics Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Scinai Immunotherapeutics's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.0184+1.4*-9.4046+3.3*0.4826+0.6*1.3122+1.0*0.0376
=-10.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was €11.05 Mil.
Total Current Assets was €1.46 Mil.
Total Current Liabilities was €1.25 Mil.
Retained Earnings was €-103.89 Mil.
Pre-Tax Income was 9.42 + -2.157 + -1.986 + -2.137 = €3.14 Mil.
Interest Expense was -1.697 + -0.274 + -0.213 + -0.0070000000000001 = €-2.19 Mil.
Revenue was 0.151 + 0.264 + 0 + 0 = €0.42 Mil.
Market Cap (Today) was €2.67 Mil.
Total Liabilities was €2.03 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1.457 - 1.254)/11.047
=0.0184

X2=Retained Earnings/Total Assets
=-103.893/11.047
=-9.4046

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(3.14 - -2.191)/11.047
=0.4826

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=2.669/2.034
=1.3122

X5=Revenue/Total Assets
=0.415/11.047
=0.0376

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Scinai Immunotherapeutics has a Altman Z-Score of -10.73 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Scinai Immunotherapeutics  (FRA:2F5) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Scinai Immunotherapeutics Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Scinai Immunotherapeutics Headlines

No Headlines